Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $12.00 → $14.00 | Buy | Maxim Group |
| 3/3/2022 | $12.00 → $13.00 | Buy | HC Wainwright & Co. |
| 2/14/2022 | $10.00 → $12.00 | Buy | HC Wainwright & Co. |
| 12/2/2021 | $9.00 → $10.00 | Buy | HC Wainwright & Co. |
| 11/5/2021 | $7.00 → $9.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | $6.00 → $7.00 | Buy | HC Wainwright & Co. |
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass
HC Wainwright & Co. analyst Yi Chen maintains Sensus Healthcare (NASDAQ:SRTS) with a Buy and raises the price target from $8 to $10.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass
Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $12.00 from $10.00 previously
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders. Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv
BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice President and General Counsel Michael J. Sardano has been promoted to President and General CounselSales Manager Christopher Machuzak has been promoted to Vice President of Sales for the West CoastSoutheast Regional Sales Manager Jeffrey Starling has been promoted to Vice President of Sales for the East Coast In addition, the Company announces the retirement of Steve Cohen, Executive Vice Pre
BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong. This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region. SRT-100 systems utilize S